Lumira Ventures

Lumira Ventures is a North American life sciences venture capital firm focused on delivering exceptional returns for investors by investing in and helping to create value in transformative life sciences companies. They measure their performance not only by financial returns but also by the impact they have on patients and healthcare systems worldwide. Their core team has worked together for over a decade, developing a unique ability to cultivate winning investment themes while closely monitoring the North American healthcare landscape. Lumira prides itself on helping top-tier biotherapeutic and medical device companies realize their vision. Lumira Ventures aims to empower a better tomorrow for patients by partnering with mission-driven entrepreneurs to build transformative life sciences companies. They focus on developing and commercializing impactful products for patients. The firm's investment approach is centered around identifying and supporting companies that can address significant unmet medical needs and improve patient outcomes. Their past investments have resulted in a substantial impact, including touching over 1 billion patient lives, targeting over 40 diseases, and contributing to the development of over 50 approved products. Portfolio companies have collectively raised over $6 billion in capital, reflecting the firm's ability to attract follow-on investment and support the growth of its portfolio companies. The firm also emphasizes its commitment to supporting the broader life sciences ecosystem, as demonstrated by their partnership with The Terry Fox Foundation to launch The Cancer Breakthrough Fund. Gerry Brunk, a Managing Director at Lumira, is a member of the Focused Ultrasound Foundation's Council. These activities highlight the firm's dedication to driving innovation and improving patient care beyond their direct investments.